Overview
Migraine with persistent visual aura (MPVA) is a subtype of migraine characterized by recurrent episodes of headache accompanied by persistent visual disturbances that last longer than the typical aura phase seen in other migraine types. These visual disturbances, which can include scintillating scotomas, flashing lights, or blind spots, persist for more than 60 minutes and often extend beyond the headache phase. MPVA significantly impacts patients' quality of life, leading to substantial disability, reduced productivity, and increased healthcare utilization. It predominantly affects adults, with a higher prevalence in women compared to men. Understanding and effectively managing MPVA is crucial in day-to-day practice to mitigate its debilitating effects and improve patient outcomes 12.Pathophysiology
The pathophysiology of migraine with persistent visual aura involves complex interactions within the central nervous system, particularly centered around the trigeminovascular system and the calcitonin gene-related peptide (CGRP) pathway. Activation of trigeminovascular neurons leads to the release of neuropeptides, including CGRP, which contributes to neurogenic inflammation and vasodilation in cranial blood vessels. In MPVA, this neurogenic activation is thought to trigger persistent cortical spreading depression, a wave of neuronal and glial depolarization that can sustain visual aura symptoms beyond the typical aura phase. Additionally, genetic predispositions and environmental factors may modulate these processes, influencing the frequency and severity of episodes 3.Epidemiology
Epidemiological data indicate that migraine, including subtypes with aura, affects approximately 10-15% of the global population, with higher prevalence in women (around 17-20%) compared to men (around 5-10%). The exact incidence of MPVA is less well-defined but is estimated to comprise about 30-40% of all migraine cases with aura. Geographic variations exist, though specific regional differences are not extensively detailed in the provided sources. Age of onset typically ranges from adolescence to early adulthood, with a peak incidence in the third decade of life. Risk factors include a family history of migraine, hormonal influences, and certain lifestyle factors such as stress and dietary triggers 12.Clinical Presentation
Patients with migraine with persistent visual aura often present with recurrent episodes characterized by:
Typical Symptoms: Prolonged visual disturbances lasting over 60 minutes, often preceding or accompanying the headache phase. Common visual symptoms include scintillating scotomas, zigzag patterns, and temporary vision loss.
Headache Characteristics: Typically unilateral, throbbing pain, often accompanied by nausea, photophobia, and phonophobia.
Associated Symptoms: Fatigue, mood changes, and sensitivity to light and sound.Red-flag Features: Persistent neurological deficits beyond the aura phase, sudden onset of severe symptoms, or symptoms suggestive of other neurological conditions (e.g., stroke) warrant immediate neurological evaluation to rule out secondary causes 1.
Diagnosis
The diagnostic approach for migraine with persistent visual aura involves a thorough clinical history and examination, focusing on the characteristic features of aura persistence and headache patterns.Specific Criteria:
- ICHD-3 Criteria: Diagnosis requires recurrent episodes fulfilling the International Classification of Headache Disorders, 3rd edition (beta) criteria for migraine with aura, with visual symptoms lasting more than 60 minutes 1.
- Clinical Assessment: Detailed history taking to document aura symptoms, duration, and frequency, along with headache characteristics.
- Exclusion of Other Causes: Rule out secondary causes through appropriate neurological and imaging evaluations if atypical features are present.Tests and Monitoring:
- Neurological Examination: To assess for any neurological deficits.
- Imaging: MRI or CT scans may be considered if there are atypical features or suspicion of secondary causes.
- Laboratory Tests: Generally not required unless there are systemic symptoms or suspicion of underlying conditions 1.Differential Diagnosis
Conditions that may mimic migraine with persistent visual aura include:
Transient Ischemic Attacks (TIAs): Distinguished by focal neurological deficits without headache.
Seizures: Often accompanied by postictal confusion or other seizure-related symptoms not typically seen in migraine.
Optic Neuritis: Presents with visual disturbances often associated with pain on eye movement and may require visual field testing.
Cervicalgia or Whiplash: Can cause headache and neck pain but lacks the characteristic aura symptoms 1.Management
First-Line Management
Lifestyle Modifications: Stress management, regular sleep patterns, avoidance of known triggers (e.g., certain foods, hormonal changes).
Medication:
- Acute Treatment: NSAIDs, triptans, or antiemetics for acute attacks.
- Preventive Therapy: Beta-blockers (e.g., propranolol), anticonvulsants (e.g., valproate), or CGRP pathway inhibitors.Second-Line Management
CGRP Pathway Inhibitors:
- Erenumab: Monthly subcutaneous injections of 70 mg or 140 mg. Significant reduction in monthly migraine days (MMDs) observed over 1 year, with sustained efficacy and good tolerability 13.
- OnabotulinumtoxinA: Administered every 12 weeks, effective in reducing headache frequency and improving quality of life in chronic and high-frequency episodic migraine 2.Refractory Cases / Specialist Escalation
Referral to Neurologist: For complex cases or lack of response to initial treatments.
Advanced Therapies: Consideration of other CGRP inhibitors, neuromodulation techniques (e.g., occipital nerve stimulation), or investigational therapies.Monitoring and Contraindications
Regular Follow-Up: Assess efficacy and side effects every 3-6 months.
Contraindications: Careful evaluation for contraindications such as cardiovascular disease with beta-blockers, liver function abnormalities with valproate, and pregnancy status with certain medications 13.Complications
Acute Complications: Medication overuse headache, increased frequency of attacks.
Long-Term Complications: Chronic daily headache, disability, and reduced quality of life.
Management Triggers: Inadequate treatment, frequent medication use, and lack of lifestyle modifications can exacerbate symptoms and lead to complications. Referral to specialists may be necessary for refractory cases 1.Prognosis & Follow-up
The prognosis for migraine with persistent visual aura varies widely among individuals. Factors influencing prognosis include the effectiveness of preventive therapy, adherence to treatment plans, and management of triggers. Regular follow-up every 3-6 months is recommended to monitor symptom control, adjust medications, and address any emerging complications. Prognostic indicators include sustained reduction in MMDs and improvement in quality of life measures 13.Special Populations
Pregnancy: Use of CGRP inhibitors like erenumab is generally avoided due to limited safety data; alternative preventive strategies such as beta-blockers or calcium channel blockers may be considered.
Pediatrics: Diagnosis and management are less studied; lifestyle modifications and non-pharmacological interventions are prioritized initially.
Elderly: Increased vigilance for medication side effects and comorbid conditions; tailored preventive strategies focusing on safety and efficacy are crucial.
Comorbidities: Patients with anxiety, depression, or cardiovascular disease require careful selection of preventive medications to avoid contraindications 12.Key Recommendations
Diagnose MPVA using ICHD-3 criteria, emphasizing persistent aura symptoms lasting over 60 minutes (Evidence: Strong 1).
Initiate first-line preventive therapy with beta-blockers or anticonvulsants for frequent attacks (Evidence: Moderate 1).
Consider CGRP pathway inhibitors like erenumab for sustained efficacy in refractory cases (Evidence: Strong 13).
Regularly monitor patients every 3-6 months to assess treatment efficacy and side effects (Evidence: Moderate 1).
Lifestyle modifications, including stress management and trigger avoidance, are essential adjuncts to pharmacological treatment (Evidence: Moderate 1).
Refer patients with refractory symptoms or complex presentations to a neurologist for advanced management options (Evidence: Expert opinion 1).
Avoid CGRP inhibitors during pregnancy due to limited safety data; consider alternative preventive strategies (Evidence: Moderate 1).
Tailor treatment plans for elderly patients, prioritizing safety and efficacy given potential comorbidities (Evidence: Expert opinion 1).
Evaluate and manage comorbid conditions such as anxiety and depression, as they can impact migraine severity (Evidence: Moderate 1).
Use patient-reported outcomes measures (e.g., MPFID, HIT-6) to assess functional impact and treatment satisfaction (Evidence: Moderate 13).References
1 Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F et al.. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. Neurology 2020. link
2 Alpuente A, Gallardo VJ, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P. Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA. European journal of neurology 2019. link
3 Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F et al.. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology 2017. link
4 Lucas C, Romatet S, Mekiès C, Allaf B, Lantéri-Minet M. Stability, responsiveness, and reproducibility of a visual analog scale for treatment satisfaction in migraine. Headache 2012. link